Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is
uncertain for the treatment of novel coronavirus disease 2019 (COVID‐19). Our goal is to …

Background Convalescent plasma (CP) has been widely used to treat COVID-19 and is
under study. However, the variability in the current clinical trials has averted its wide use in …

Abstract Introduction South America is one of the regions most affected by the COVID‐19
pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection …

Background The efficacy of convalescent plasma (CP) for the treatment of coronavirus
disease 2019 (COVID-19) remains unclear. Methods In a matched cohort analysis of …

The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease
(COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 …

Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …

COVID-19 is a global pandemic associated with increased morbidity and mortality.
Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We …

Background The effects of convalescent plasma (CP) therapy in hospitalised patients with
coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect of …

Background The role of convalescent plasma therapy for patients with coronavirus disease
2019 (COVID‐19) is unclear. Methods We retrospectively compared outcomes in a cohort of …

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the
treatment for other emerging viral infections. However, the quality control of CP and …